CD8A and plasma cell myeloma: We used our syngeneic SCT systems characterized by CD8+ T cell control since the potency of immune control in our ASCT model, where donor T cells are myeloma experienced, makes any substantial increases in survival with checkpoint inhibition difficult to ascertain (1).